Lipids for use in lipid nanoparticle formulations
AssigneeAcuitas Therapeutics, Inc.
InventorXinyao Du
Life of this patent
Estimating the term…
Abstract
Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Claims26
A compound having the following structure (I):
- or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
- L1 is —O(C═O)R1 or —(C═O)OR1;
- L2 is —O(C═O)R2 or —(C═O)OR2;
- G1 and G2 are each independently C4-C10 alkylene;
- G3 is C2 or C3 alkylene,
- R1 and R2 are each independently branched C6-C24 alkyl or branched C6-C24 alkenyl;
- R3 is —N(R4)R5;
- R4 is C1-C12 alkyl;
- and
- R5 is substituted C1-C12 alkyl;
- and
- wherein each alkyl, alkenyl and alkylene is unsubstituted unless otherwise specified.
2-6. (canceled)
8-10. (canceled)
14-17. (canceled)
19-21. (canceled)
23-24. (canceled)
A compound having one of the following structures:
33-47. (canceled)
A lipid nanoparticle comprising a compound having the following structure (I):
- or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
- L1 is —O(C═O)R1, —(C═O)OR1, —C(═O)R1, —OR1, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc or —NRaC(═O)OR1;
- L2 is —O(C═O)R2, —(C═O)OR2, —C(═O)R2, —OR2, —S(O)xR2, —S—SR2, —C(═O)SR2, —SC(═O)R2, —NRdC(═O)R2, —C(═O)NReRf, —NRdC(═O)NReRf, —OC(═O)NReRf;
- —NRdC(═O)OR2 or a direct bond to R2;
- G1 and G2 are each independently C2-C12 alkylene or C2-C12 alkenylene;
- G3 is C1-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene or C3-C8 cycloalkenylene;
- Ra, Rb, Rd and Re are each independently H or C1-C12 alkyl or C1-C12 alkenyl;
- Rc and Rf are each independently C1-C12 alkyl or C2-C12 alkenyl;
- R1 and R2 are each independently branched C6-C24 alkyl or branched C6-C24 alkenyl;
- R3 is —N(R4)R5;
- R4 is C1-C12 alkyl;
- R5 is substituted C1-C12 alkyl;
- and
- x is 0, 1 or 2, and
- wherein each alkyl, alkenyl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, aryl and aralkyl is independently substituted or unsubstituted unless otherwise specified.
Dependencies are inferred from the claim text.